CTxONE plays a role in a number of research collaborations. The following projects are included in the CTxONE portfolio:
Chromatin modifying enzymes
Description: Two pre-clinical cancer programs which target proteins that drive the development of solid and blood-borne cancers
Status: Partnered with Pfizer Inc.
Description: PRMT5 inhibitor for the treatment of blood disorders and haematological and solid tumours
Status: Partnered with Cancer Research Technology UK